This therapeutic strategy targets voltage-gated ion channels — sodium (Nav), calcium (Cav), and potassium (Kv) channels — to restore normal neuronal excitability and prevent excitotoxic cell death across multiple neurodegenerative diseases.
Ion channel dysfunction is a fundamental early event in neurodegeneration. Multiple converging mechanisms disrupt voltage-gated channel function:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | Channel modulation is established in epilepsy/migraine but underutilized in neurodegeneration; novel multi-target approach |
| Mechanistic Rationale | 9 | Strong genetic and mechanistic evidence; ion channel dysfunction documented across AD, PD, ALS, FTD |
| Root-Cause Coverage | 8 | Targets excitotoxicity (upstream of protein aggregation), not just downstream symptoms |
| Delivery Feasibility | 7 | Existing CNS-penetrant channel modulators (phenytoin, lamotrigine, zonisamide); reformulation needed |
| Safety Plausibility | 7 | Known drug class with established safety profiles; cardiac safety monitoring required for some targets |
| Combinability | 9 | Synergizes with glutamate antagonists, autophagy enhancers, and metabolic therapies |
| Biomarker Availability | 8 | EEG for neuronal excitability, calcium imaging, Nav current measurements in iPSC neurons |
| De-risking Path | 8 | Repurposing candidates (zonisamide, lamotrigine) can enable rapid Phase 2 trials |
| Multi-disease Potential | 10 | Applicable across AD, PD, ALS, FTD, HD — broad excitability dysfunction |
| Patient Impact | 7 | Addresses early excitability changes before irreversible neuronal loss |
Total: 78/100
| Disease | Score | Evidence |
|---|---|---|
| Alzheimer's Disease | 9 | Nav1.6 downregulation in temporal cortex (PMID:31797452); Cav1.3 overexpression in hippocampus; HCN dysfunction |
| Parkinson's Disease | 8 | L-type calcium channel dysfunction in dopaminergic neurons; hyperexcitability in PD models |
| ALS | 9 | Nav1.6 dysfunction at nodes of Ranvier; excitotoxicity is ALS hallmark; Kv channel alterations |
| FTD | 7 | Ion channel dysregulation in frontotemporal circuits; TDP-43 interactions with channel proteins |
| PSP | 6 | Brainstem circuit hyperexcitability; limited but emerging evidence |
| Huntington's | 6 | Excitotoxicity in medium spiny neurons; Kv channel alterations |
| Aging | 8 | Ion channel dysfunction is a core feature of brain aging; therapeutic window |
Preclinical validation (6-12 months)
IND-enabling studies (12-18 months)
Clinical development (2-3 years)